Answers are grounded in this paper and cite their sources.
Objective This retrospective single-arm case series described the changes in arterial oxygenation in patients with hepatopulmonary syndrome (HPS) secondary to hypopituitarism who received recombinant human growth hormone (rhGH) replacement. Methods A total of 21 patients were enrolled, with etiologies including pituitary stalk interruption syndrome (n = 3), post-resection craniopharyngioma (n = 11), and sellar germ cell tumors (n = 7). The median interval from hypopituitarism diagnosis to HPS onset was 9 years. Ten patients received rhGH therapy. The 11 non-GH patients served as a baseline descriptive comparison; follow-up oxygenation data were available for only 3, precluding longitudinal between-group comparison. Results Among the ten treated patients, rhGH therapy was associated with average improvement in PO 2 (from 48.6 ± 4.2 mmHg to 91.0 ± 6.0 mmHg; P = 0.0006) and average reductions in P(A–a)O 2 (from 60.8 ± 4.8 mmHg to 12.2 ± 5.5 mmHg; P < 0.0001). Eight of ten treated patients maintained normal PO 2 levels during extended therapy lasting 8 to 84 months, while two showed partial improvement without reaching the normal threshold (41→57 mmHg and 46→61 mmHg). In three patients with available data, liver stiffness measurement decreased significantly after 7 to 13 months of rhGH treatment (from 33.0 ± 7.6 kPa to 24.7 ± 6.4 kPa). Given the small number of patients (n = 3), these data are presented descriptively only. Conclusion rhGH replacement was associated with significantly improved oxygenation and sustained therapeutic benefits in patients with hypopituitarism-associated HPS, supporting further investigation of its potential as an adjunctive therapy; however, randomized controlled studies are needed.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: